Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AC682 |
| Synonyms | |
| Therapy Description |
AC682 is a small molecule Esr1 (Er alpha) degrader, which potentially decreases Esr1 (Er alpha) protein levels and inhibits tumor growth (Cancer Res 2021;81(4 Suppl):Abstract nr PS18-09). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AC682 | AC-682|AC 682 | Hormone - Anti-estrogens 31 | AC682 is a small molecule Esr1 (Er alpha) degrader, which potentially decreases Esr1 (Er alpha) protein levels and inhibits tumor growth (Cancer Res 2021;81(4 Suppl):Abstract nr PS18-09). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05080842 | Phase I | AC682 | A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer | Terminated | USA | 0 |